LYRA Stock Analysis: Buy, Sell, or Hold?
LYRA - Lyra Therapeutics, Inc. Common Stock
$0.50
-0.83 (-62.50%)
▼
5d:
-61.92%
30d:
-62.5%
90d:
-87.62%
WAIT
LOW Confidence
Analysis Updated: Mar 16, 2026 12:00 AM ET
Earnings: Mar 12, 2026
0d
Get Alerted When LYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LYRA is down 61.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LYRA is down 61.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYRA is currently trading at $0.49, which is considered oversold relative to its 30-day fair value range of $1.02 to $1.45.
Technical Outlook: Technically, LYRA is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 62.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.00 (+3132.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYRA is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 62.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.00 (+3132.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.02 -
$1.45
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-62.5%)
- BULLISH: Trading 3132.3% below Wall St target ($16.00)
- WARNING: Recommendation downgraded due to -61.9% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.02 -
$1.45
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.42
Current Trend
Strong Downtrend
Technical data as of
Mar 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.07
Wall Street Target
$16.00
(+3132.3%)
Revenue Growth (YoY)
-87.2%
Share & Embed Analysis
Last updated: April 02, 2026 5:49 PM ET
Data refreshes hourly during market hours. Next update: 6:49 PM
Data refreshes hourly during market hours. Next update: 6:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason Cavalier
SELL
769 shares
2026-01-06
Maria Palasis
SELL
1702 shares
2026-01-06
Perceptive Advisors Llc
SELL
31810 shares
2025-11-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 61 BUY |
